ALS: Long-Term Tofersen Data for SOD1-ALS and New Gene Therapy Advances
Share
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that destroys motor neurons in the brain and spinal cord. It leads to muscle weakness, paralysis, and eventually respiratory failure. Most patients live only 2–5 years after diagnosis, and there is still no cure. Approximately 10–20% of cases are linked to known genetic mutations (SOD1, C9orf72, TARDBP, etc.).
Until recently, approved treatments only modestly slowed progression. Two recent developments — a precision genetic therapy with long-term data and new gene-therapy platforms — are changing the outlook, at least for certain genetic forms of ALS.
Long-Term Tofersen (Qalsody) Results in SOD1-ALS
Tofersen is an antisense oligonucleotide (ASO) designed to reduce production of toxic SOD1 protein in people with SOD1 gene mutations (about 2% of all ALS cases). It received accelerated FDA approval in 2023.
Updated long-term data (December 2025, published in JAMA Neurology):
- Patients who started tofersen early showed significantly slower functional decline.
- Some participants maintained or even improved strength and mobility over multiple years.
- Biomarker reductions (neurofilament light chain) correlated with better clinical outcomes.
- A separate prevention trial is now underway for people who carry SOD1 mutations but have not yet developed symptoms.
This is the first time a gene-targeted therapy has shown durable benefit in a genetic form of ALS.
Broader Gene Therapy Pipeline
Newer approaches are expanding beyond SOD1:
- Insmed’s INS1202 and other AAV-based gene therapies entered first-in-human trials in early 2026.
- Several companies are developing therapies targeting TDP-43 (the protein that clumps in ~97% of ALS cases) and other genetic drivers.
- Early data suggest these one-time treatments may slow or even halt progression in select patients.
While most of these are still in early phases, the pace of progress is the fastest ALS research has ever seen.
What These Developments Mean for Families
| Approach | Current Status | Key Advantage | Limitations |
|---|---|---|---|
| Tofersen (SOD1-ALS) | Approved + long-term data | First gene-targeted therapy with durable benefit | Only for SOD1 mutation (~2% of patients) |
| New Gene Therapies | Phase 1 trials ongoing | One-time treatment; broader genetic targets | Still early; larger trials needed |
These advances are most impactful for people with known genetic forms of ALS, but they are also accelerating research into non-genetic (sporadic) ALS.
If you or a loved one has been diagnosed with ALS, independent research into genetic testing, clinical trials, and access pathways can make a real difference in the options available. Our team offers a free case assessment to review your records and outline realistic next steps — no obligation.